French biotech stock soars 30% after new data on experimental medicine

According to CNBC, French biotech company Abivax saw its stock soar thirty percent on Tuesday, following the release of new trial data for obefazimod, the company's experimental drug for bowel disease.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton